The routine is becoming a habit rather than a conscious effort
People have reported surprising effects from these medications, including physical and mental changes
Semaglutide 2.4 mg weekly showed an average weight loss of 17.3% at 68 weeks, though two-thirds of this loss was regained after withdrawal, reinforcing the need for continued therapy [10]
jamanetwork.com/journals/jamap : JAMA Psychiatry study highlights (semaglutide in schizophrenia spectrum disorders): Studied adults with schizophrenia spectrum disorders treated with clozapine or olanzapine, two antipsychotics strongly linked to weight gain and metabolic syndrome Participants were randomized to receive semaglutide (GLP-1 receptor agonist) vs placebo, in addition to usual psychiatric care Significant weight loss was observed in the semaglutide group compared with placebo Improved glycemic control including reductions in HbA1c and fasting glucose, even in early metabolic dysregulation Beneficial effects seen early, suggesting potential for prevention of diabetes rather than late treatment Semaglutide was generally well tolerated, with no worsening of psychotic symptoms Addresses a major unmet need, people with serious mental illness die earlier largely due to cardiometabolic disease Supports the role of GLP-1 receptor agonists as an adjunct treatment to mitigate antipsychotic-induced metabolic harm Bottom line: A promising strategy to reduce weight, diabetes risk, and long-term cardiovascular mortality in patients on high-risk antipsychotics
Most of the GLP-1 medications work only on the GLP-1 receptor
